AstraZeneca’s (AZN) Saphnelo has been approved in the European Union, EU, for subcutaneous self-administration as a pre-filled pen for adult ...

AstraZeneca PLC (NASDAQ:AZN) operates across global healthcare markets through advanced research pathways, biopharmaceutical ...

The move would onshore production of its rare disease products at an existing facility in Frederick and build a clinical ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic ...

AstraZeneca’s AZN first-quarter 2023 core earnings of 96 cents per American depositary share (ADS) beat the Zacks Consensus Estimate of 86 cents and our model estimate of 85 cents. Core earnings of $1 ...

Currently, the S&P 500 and many sectors are outperforming the healthcare sector, presenting an opportunity to explore assets within this sector during the current period of apathy towards it.

TD Cowen raised the firm’s price target on AstraZeneca (AZN) to $105 from $95 and keeps a Buy rating on the shares. The firm said the company has ...

The pharmaceutical company AstraZeneca can move forward with an addition to one of the buildings on its Frederick campus, after getting approval from the city of Frederick’s Planning Commission. The ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp., AstraZeneca PLC ...

AstraZeneca recently bundled its COVID-19 vaccine and antibody treatment into a separate division. But there’s a chance that the new unit might not stay with it for long. The British drugmaker is ...

Since I covered AstraZeneca last October, shares have narrowly outperformed the S&P 500 index. Thanks to impressive results throughout the business, the company's total revenue and core EPS jumped in ...